ResMed Inc. RMD NYSE · Healthcare · United States
$241.03 +0.63% +$1.50
Summary
89 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 28 USD is left as net profit.
- Earnings per share grew by 20% a year over the last 3 years.
- It earns 21 USD a year on every 100 USD of invested capital.
- It has raised its dividend 13 years in a row and pays out only 22% of profit.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.1 USD for 1 USD of yearly profit. Over the last five years it was 29.8 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 10% a year. For the next fiscal year analysts expect revenue to grow by 3.1%. Earnings per share grew by 20% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 39 USD
- Research and development 6.9 USD
- Sales and administration 21 USD
- Taxes and other 5.3 USD
- Net profit 28 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 28 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.05%
- Paid out of profit
- 22%
- Raised in a row
- 13 years
You receive $2.52 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 14
- Hold 17
- Sell 5
Today's price within the analysts' price targets
The average target of $246.89 is 2.2% above today's price. 39% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Sleep And Respiratory 88%
- Software As Service 12%
By region
- U [S] 64%
- Global 36%
Sleep And Respiratory brings in 88% of revenue. Software As Service grew fastest, by 13% a year.
Segments in detail